Loading clinical trials...
Loading clinical trials...
An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease
Conditions
Interventions
LAI plus multi-drug regimen
Locations
2
United States
Oregon Health & Science University
Portland, Oregon, United States
University of Texas Health Science Center
Tyler, Texas, United States
Start Date
October 1, 2016
Primary Completion Date
October 31, 2019
Completion Date
December 31, 2019
Last Updated
March 4, 2020
NCT07094711
NCT03421743
NCT04677543
NCT04154826
NCT02340897
Lead Sponsor
Kevin Winthrop
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions